desferrioxamine-b-succinyl-phenylalanine(1)-octreotide and Sarcoidosis

desferrioxamine-b-succinyl-phenylalanine(1)-octreotide has been researched along with Sarcoidosis* in 3 studies

Reviews

1 review(s) available for desferrioxamine-b-succinyl-phenylalanine(1)-octreotide and Sarcoidosis

Article	Year
Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:9 We herein report a case of renal sarcoidosis presenting as acute kidney injury (AKI) during treatment with etanercept for rheumatoid arthritis. Blood tests showed a high level of angiotensin-converting enzyme and a renal biopsy demonstrated non-caseating granulomatous tubulointerstitial nephritis. The administration of high-dose steroid therapy (1 mg/kg) and discontinuation of etanercept resulted in an improvement in the patient's renal function. Although renal sarcoidosis induced by anti-tumor necrosis factor (TNF) therapy is an extremely rare manifestation, this case suggests that renal sarcoidosis should be considered in the differential diagnosis of AKI in patients receiving anti-TNF therapy, as providing an early diagnosis and treatment is important for preventing irreversible renal impairment. Topics: Acute Kidney Injury; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Deferoxamine; Diagnosis, Differential; Etanercept; Female; Gallium Radioisotopes; Humans; Octreotide; Radionuclide Imaging; Sarcoidosis; Treatment Outcome; Tumor Necrosis Factor-alpha	2015

Article

Year

Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review.

Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:9

We herein report a case of renal sarcoidosis presenting as acute kidney injury (AKI) during treatment with etanercept for rheumatoid arthritis. Blood tests showed a high level of angiotensin-converting enzyme and a renal biopsy demonstrated non-caseating granulomatous tubulointerstitial nephritis. The administration of high-dose steroid therapy (1 mg/kg) and discontinuation of etanercept resulted in an improvement in the patient's renal function. Although renal sarcoidosis induced by anti-tumor necrosis factor (TNF) therapy is an extremely rare manifestation, this case suggests that renal sarcoidosis should be considered in the differential diagnosis of AKI in patients receiving anti-TNF therapy, as providing an early diagnosis and treatment is important for preventing irreversible renal impairment.

Topics: Acute Kidney Injury; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Deferoxamine; Diagnosis, Differential; Etanercept; Female; Gallium Radioisotopes; Humans; Octreotide; Radionuclide Imaging; Sarcoidosis; Treatment Outcome; Tumor Necrosis Factor-alpha

2015

Other Studies

2 other study(ies) available for desferrioxamine-b-succinyl-phenylalanine(1)-octreotide and Sarcoidosis

Article	Year
A Wig Sign. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:21 Topics: Aged; Anti-Inflammatory Agents; Deferoxamine; Humans; Male; Octreotide; Prednisolone; Sarcoidosis; Scalp; Tomography, Emission-Computed; Treatment Outcome	2015
Tc-99m MDP and Ga-67 citrate scintigraphic findings in sarcoidosis with osseous involvement. Clinical nuclear medicine, 2001, Volume: 26, Issue:5 Topics: Bone Diseases; Deferoxamine; Humans; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Sarcoidosis; Technetium Tc 99m Medronate	2001